Comments
Drug firm Zydus Cadila has received final approval from the US health regulator to market Amitriptyline hydrochloride tablets used for treatment of depression in the American market.
The company has received final approval from the United States Food and Drug Administration (USFDA) to market the tablets in strengths of 10mg, 25mg, 50mg, 75mg, 100mg and 150mg, Cadila Healthcare, the listed entity of the group said in a BSE filing today.
The drug, used in treating depression, will be manufactured at the group’s formulations facility at SEZ Ahmedabad, it added.
“The group now has more than 160 approvals and has so far filed over 300 abbreviated new drug applications (ANDAs) since the commencement of the filing process by the company,” it added.
Comments
COMMENT NOW
Comments
Comments have to be in English, and in full sentences. They cannot be abusive or personal. Please abide by our community guidelines for posting your comments.
We have migrated to a new commenting platform. If you are already a registered user of TheHindu Businessline and logged in, you may continue to engage with our articles. If you do not have an account please register and login to post comments. Users can access their older comments by logging into their accounts on Vuukle.